HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Genomics and proteomics are changing discovery, development and clinical use of dementia drugs.

Abstract
Drug discovery as well as the optimization of drug use in dementia is at the verge of a new stage, which is being brought about by the broad and systematic application of functional genomics and proteomics. Alzheimer's disease is the focus of this transition, whereas vascular dementia can benefit from the spill over from cardiovascular research, which is already more developed. This review discusses the stratification of Alzheimer's patients for cholinesterase inhibitor therapy according to genetic polymorphisms and the modulating roles of mutations in the genes coding for angiotensin-converting enzyme, presenilin, cathepsin and potassium channels, which are all hotbeds for 'omics' applications. Lastly, the case for humanin is discussed as an example of the discovery of a potentially novel neuroprotective pathway that could be exploited for dementia drugs.
AuthorsHermann Am Mucke
JournalExpert opinion on drug discovery (Expert Opin Drug Discov) Vol. 2 Issue 3 Pg. 313-9 (Mar 2007) ISSN: 1746-0441 [Print] England
PMID23484643 (Publication Type: Journal Article)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: